BTP Analytics Ltd

Epigenetic diagnostics for earlier cancer detection

We develop and validate molecular diagnostic tests for cancer based on epigenetics. Our current focus is a test for invasive breast cancer, aimed at earlier and more objective detection than visual assessment of tissue slides allows — including at Stage I, where detection is hardest.

What we do

Detection of invasive breast cancer at its earliest stage still rests largely on a pathologist's visual assessment of tissue slides. BTP Analytics is developing a molecular diagnostic test that uses epigenetic signatures to provide an objective, measurable basis for that determination.

Our work is grounded in DNA methylation patterns that differ consistently between tumour and normal tissue. Our longer-term aim is for molecular testing to become standard practice.

Where we are

BTP Analytics is pre-revenue and currently at the licensing and partnership-seeking stage. The test is in development and is not yet available for clinical use.

We are engaged with several Canadian innovation and life-sciences organizations as part of our development programme.

What we are looking for

A strategic advisor. We are actively seeking an advisor with senior industry experience in diagnostics or oncology, to help guide the company through licensing, partnership, and the route to clinical validation.

Licensing and partnership conversations. We are open to discussions with diagnostics companies, oncology-focused organizations, and investors active in early-stage life sciences.

Request the pitch deck

To request our pitch deck, please use the form below. We respond to all enquiries.